Beta-blockers are commonly used as an anti-premature drug because they can effectively inhibit the activity of excessive catecholamines and their stimulating effect on the heart, as well as improve the blood supply to the heart, reduce the oxidative stress of the myocardium and a series of other effects, all of which can reduce the abnormalities of the heart’s autoregulation, triggering and folding, all of which are a basic cause of arrhythmias such as premature beats. Beta-blockers are used in the treatment of premature beats with the following precautions: First, not all patients with premature beats need to use betalactam. Secondly, in cases without organic pathology, such as physiological conditions, which cause episodic premature beats and no obvious symptoms, it is possible not to use betalactam for treatment, but in patients with very high rate of organic premature beats, which cause corresponding symptoms, especially in combination with hypertension or coronary artery disease, which require betalactam for treatment of the disease, use betalactam for The use of Betalac for the treatment of premature beats or for the treatment of this disease can be very useful. However, in the treatment of premature beats, it is important to note the following: First, betalac is not indicated for patients with bradycardia. The second point is that it is not suitable for patients with bronchial asthma or chronic obstructive pulmonary disease (COPD), such as chronic lung disease. The third point is that patients with perivascular occlusive lesions are also not suitable for treatment with Betalac because of the adverse side effects.